← IOVA: big moves and long-term fundamentals中文

Iovance Biotherapeutics: The Long View

What the filings say about its story, dilution and cash runway.

Last updated Nov 12, 2026 · Reflects: 10-K FY2025, the 10-Q for Q3 2026 and releases through Nov 5, 2026

This page is information, not investment advice.

Sources used most:

1. In one paragraph

Last updated Nov 12, 2026. Reflects the 10-K FY2025, the 10-Q for Q3 2026 and releases through Nov 5, 2026.

Iovance sells Amtagvi (lifileucel), a one-time cell therapy for advanced melanoma made from each patient’s own tumour-fighting immune cells (tumour-infiltrating lymphocytes, or TIL), plus Proleukin (interleukin-2, or IL-2, an immune-stimulating drug) given as part of the Amtagvi regimen. In 2025 revenue was $263.5M: Amtagvi about $220M (about 83%) and Proleukin about $44M (about 17%), with 98% of sales in the US. It reports one segment and still loses money; it has funded itself mainly by selling shares (10-K, notes 7 and 12; Q4 2025 release).

  • Amtagvi has US accelerated approval (Feb 2024) for melanoma that has worsened after a drug blocking PD-1 (an immune-system checkpoint protein) and, for tumours with a BRAF V600 gene change, a BRAF inhibitor with or without a MEK inhibitor (targeted drugs that block proteins involved in cancer-cell growth). A Phase 3 trial, TILVANCE-301, is meant to confirm the benefit. Canada and Australia have also approved it (Q2 2026 release).
  • In the first nine months of 2026, revenue was $292.2M; Q3 alone was $121.5M, of which US Amtagvi about $102M and Proleukin about $20M (10-Q Q3 2026; Q3 2026 release). More than 1,000 patients have been treated with commercial Amtagvi.
  • Iovance makes Amtagvi in its own Philadelphia plant; its outside manufacturer stopped production in Q1 2026 (10-K, note 15).
  • Lung cancer is the next planned use: Iovance plans to file for approval in previously treated non-squamous lung cancer in 2027 (Oct 29 release).

2. Story so far

Last updated Nov 12, 2026. Reflects filings and releases through Nov 5, 2026 and our coverage of Oct 29, 2026.

In short: Iovance bought Proleukin in 2023 and won US approval for Amtagvi in 2024, funded largely by selling new shares. A slower-than-planned launch led it to cut its 2025 sales forecast by roughly 40% and lay off about a fifth of its staff. In 2026 sales grew quickly and it raised its forecast in September, but its October lung cancer update showed responses concentrated in one subgroup of patients.

Date Milestone Source
May 18, 2023 Buys worldwide Proleukin rights from Clinigen for $210.2M cash, plus a $52.6M payment due on Amtagvi’s approval and payments at double-digit rates on global net sales (as defined in the agreement) for 12 years 10-K FY2025, note 4
Jul 13, 2023 Sells 23.0M shares at $7.50 in a public offering ($161.5M net) 10-K FY2025, note 10
Feb 16, 2024 ★ FDA grants Amtagvi accelerated approval for advanced melanoma, the first approved T cell therapy for a solid tumour Release
Feb 22, 2024 Sells 23.0M shares at $9.15 ($197.4M net) 10-K FY2025, note 10
Feb 27, 2025 Reaffirms 2025 revenue guidance of $450–475M Q4 2024 release
May 8, 2025 ★ Cuts 2025 revenue guidance to $250–300M, citing launch dynamics Q1 2025 release
Aug 7, 2025 Restructuring: about 19% of staff cut and more than $100M of yearly savings expected; cash runway “into the fourth quarter of 2026” Q2 2025 release; 10-Q Q2 2026, risk factors
Nov 2025 Updated registrational lung cancer data: 25.6% of 39 patients respond Release, Nov 3, 2025; Oct 29 release
Feb 24, 2026 2025 revenue $263.5M, within guidance; runway “into the third quarter of 2027” Q4 2025 release
Jun 3, 2026 Australia approves Amtagvi, its third market Release
Aug 6, 2026 Record Q2 revenue of $99.3M (+66% year over year); runway “into 2H28” Q2 2026 release
Sep 29, 2026 ★ Raises 2026 revenue guidance to $410–420M from $350–370M; Stock Analysis reports a 31% rise that day, to $14.45 8-K; Stock Analysis
Oct 28–29, 2026 ★ Calls its lung cancer cohorts “positive” (Oct 28), then reports a 24.6% response rate in 69 patients, with most responses in a subgroup identified retrospectively (by looking back at existing data); Stock Analysis reports a 35.45% fall that day, to a $9.56 close. Start of our coverage: Why Iovance stock fell Webcast notice; Oct 29 release; Stock Analysis
Nov 5, 2026 Record Q3 revenue of $121.5M (+80%); gross margin about 60%; Q3 operating cash use about $4.5M (our calculation); 2026 guide of $410–420M kept; runway “well into 2029” Q3 2026 release, 10-Q Q3 2026

3. Latest quarter: did the story change?

Last updated Nov 12, 2026. Reflects Q3 2026 (10-Q and release, Nov 5, 2026) and the Oct 29 lung cancer update.

Bottom line: Iovance’s Q3 filings show another record quarter for sales and its highest gross margin yet, and cash use fell to about $9M (our calculation). The 2026 revenue guide held, and the runway estimate moved out to “well into 2029”. The lung cancer filing plan is unchanged, but the October update put most responses in a subgroup that still has to be tested prospectively.

Driver Last quarter → this quarter Management: before → now Signal
Revenue Q2 $99.3M → Q3 $121.5M (US Amtagvi about $91M → about $102M; Proleukin about $9M → about $20M) 2026 guide $410–420M (Sep 29) → “on track” for $410–420M (Nov 5) Better
Gross margin (company measure, excluding depreciation and amortisation) Q2 56% → Q3 about 60% Further gains expected, “excluding occasional one-time items” (Aug 6) → same (Nov 5) Better
Cash use and runway Free cash flow (operating cash flow less capital spending): Q2 −$66.3M → Q3 about −$9.2M (our calculation)1; $87.9M raised from share sales in Q3 Runway “into 2H28” (Aug 6) → “well into 2029” (Nov 5) Better
Lung cancer (IOV-LUN-202) 24.6% response rate in 69 patients (Oct 29) → unchanged (Nov 5); a biomarker-selected cohort (patients picked by measurable tumour features), POSITILITY, starts enrolling in November Filing still planned for 2027 (Oct 29) → same; independent review and FDA discussions ongoing (Nov 5) Watch

Sources: Q2 2026 release, Q3 2026 release, 10-Q Q2 2026, 10-Q Q3 2026, 8-K, Sep 29, Oct 29 release.

Unresolved questions: whether the FDA accepts a 2027 filing in the broad lung cancer group; whether the 59.1% response rate in the subgroup (13 of 22 patients) holds up when tested prospectively (with patients chosen in advance); whether the low Q3 cash use lasts; and how Iovance funds itself now that its $350M share-sale agreement is used up. Frederick Vogt, Ph.D., J.D., signs the filings as Interim CEO and President.

Lung cancer update details (Oct 29, 2026)
  • As of the Oct 14 data cutoff, 17 of 69 patients responded (15 confirmed, 2 awaiting confirmation); independent radiology review is ongoing. About 80 patients are expected in the final dataset.
  • A retrospective analysis found a subgroup (tumours without KRAS or HER2 mutations, in current or former smokers) of 22 of 69 patients that accounted for 13 of the 17 responses (59.1%). Iovance will test it prospectively in POSITILITY, which it intends to support a registration path, subject to FDA feedback, and plans a first-line trial in the same kind of patients, OPTILISM, in 2027.
  • Source: Oct 29 release.

4. Buybacks vs real dilution (5 years)

Last updated Nov 12, 2026. Reflects the equity statements in the 10-K FY2023, 10-K FY2025 and 10-Q Q3 2026.

Dilution in one line: shares outstanding (common plus convertible preferred, as converted) rose 190% from Dec 31, 2021 to Sep 30, 2026, about 25.2% a year compounded. If you owned 1% of Iovance at the end of 2021, you’d own about 0.34% on Sep 30, 2026 without buying more (our calculation)2. None of the new shares were offset by buybacks. Our scale: High (over 3% a year).

Our rule of thumb: under 1% a year low, 1–3% moderate, over 3% high.

Change in shares outstanding, Dec 31, 2021 to Sep 30, 2026FY2022 +19.3%, FY2023 +35.8%, FY2024 +19.0%, FY2025 +34.3%, 9M 2026 +12.2%. Total +190.5% since Dec 31, 2021.0%+50%+100%+150%+200%FY2022: +19.3% in the period; +19.3% since Dec 31, 2021+19.3%FY2022FY2023: +35.8% in the period; +62.0% since Dec 31, 2021+35.8%FY2023FY2024: +19.0% in the period; +92.7% since Dec 31, 2021+19.0%FY2024FY2025: +34.3% in the period; +158.8% since Dec 31, 2021+34.3%FY20259M 2026 (part year): +12.2% in the period; +190.5% since Dec 31, 2021+12.2%9M 2026+190.5%since Dec 31, 2021

Change in the period Total since Dec 31, 2021 Part year

Shares outstanding at period end (all classes): 159.9M on Dec 31, 2021, 464.6M on Sep 30, 2026, +190.5% (our calculation). A bar below zero means the count fell (net buybacks).

Common stock plus convertible preferred stock as converted (Series A and Series B), from the filings.

Period endShares outstandingChangeBuybacks (fiscal year)Stock-based pay (fiscal year)Stock pay as % of revenue
9M 2026 (Sep 30, 2026)464.6M+12.2%———
FY2025 (Dec 31, 2025)414.0M+34.3%—$62M23%
FY2024 (Dec 31, 2024)308.2M+19.0%—$110M67%
FY2023 (Dec 31, 2023)259.1M+35.8%—$63M5267%
FY2022 (Dec 31, 2022)190.8M+19.3%—$84M—
FY2021 (Dec 31, 2021)159.9M——$70M—

Shares outstanding from the balance sheets in the company's 10-K and 10-Q filings; buybacks (cash spent) and stock-based pay from its 10-Ks, via SEC EDGAR.

How we calculated this

Share sales for cash supplied 96% of the new shares (our calculation)3. Iovance has bought back no stock. Employee rows are net of shares withheld for taxes.

Bridge (millions of shares, common plus preferred as converted) 2022 2023 2024 2025 9M 2026 Total
Start of period 159.9 190.8 259.1 308.2 414.0 159.9
Share sales for cash (public offerings and at-the-market sales of new shares into the open market) 29.8 67.1 46.1 101.9 47.6 292.5
Stock pay and employee plans (restricted stock units, options, share purchase plan) 1.0 1.2 3.0 3.9 3.0 12.1
Acquisitions or convertible notes 0 0 0 0 0 0
Buybacks 0 0 0 0 0 0
End of period 190.8 259.1 308.2 414.0 464.6 464.6
  • Preferred stock: 194 Series A shares (convertible into 97,000 common) and Series B shares convertible one-for-one (2.84M until 2025, when 0.91M converted; 1.93M at Sep 30, 2026). On common shares alone the rise is 195% (our calculation)4.
  • There have been no stock splits since 2021. Common shares were 462.66M on Oct 27, 2026, the 10-Q cover date (10-Q Q3 2026, cover).
  • Totals use unrounded filing figures (10-K FY2023, 10-K FY2025, 10-Q Q3 2026, equity statements).

Prices paid and received:

Period Shares bought back Average price paid Spent Shares sold for cash Average price received Raised Sources
2022 — — — 29.79M $6.52 $194.2M (our calculation) 10-K FY2023, note 10: at-the-market sales, $189.5M net
2023 — — — 67.08M $7.16 (our calculation) $480.6M (our calculation) 10-K FY2025, note 10: 23.0M shares at $7.50 ($172.5M) and 44.08M at-the-market shares at a $6.99 average
2024 — — — 46.14M $8.98 (our calculation) $414.6M (our calculation) 10-K FY2025, note 10: 23.01M shares at $9.15 ($210.6M) and 23.13M at-the-market shares at an $8.82 average
2025 — — — 101.90M $3.07 $312.8M (our calculation) 10-K FY2025, note 10: at-the-market sales, $306.3M net
2026 to date (Jan 1–Sep 30) — — — 47.59M $5.06 (our calculation) $240.6M (our calculation) 10-Q Q1 2026: 24.92M shares at $4.03; 10-Q Q2 2026, note 9: 14.00M at $3.61; 10-Q Q3 2026: 8.67M at $10.34

Iovance has sold shares every year and bought none back. About half of the shares sold for cash came in 2025 and the first half of 2026, at average prices of $3–4, below the $6.52–8.98 averages of 2022–24; the Q3 2026 sales averaged $10.34 and used up the $350M agreement with Jefferies. Gross amounts and averages are our calculation5.

Basis and details
  • At-the-market averages are the company’s weighted averages; raised is gross proceeds before commissions and costs (net figures are in the sources column). Prices are per share; no splits in the period.
  • Excluded: employee option exercises and share-purchase-plan sales. Shares withheld for employee taxes are not buybacks.
  • In Q3 2026 Iovance sold 8.67M shares at a $10.34 average for about $87.9M net, which completed the $350M at-the-market agreement with Jefferies (10-Q Q3 2026).
  • For reference, Stock Analysis reports closing prices of $14.81 on Oct 28, 2026, the day before the lung cancer update, and $7.63 on Nov 12, 2026 (Stock Analysis).
Stock-based pay 2022 2023 2024 2025 9M 2026
$M 84.0 62.6 109.6 61.6 34.8
% of revenue (our calculation)6 No revenue Not meaningful (revenue $1.2M) 67% 23% 12%

Stock pay has fallen since 2024. At Jun 30, 2026, 17.6M options and 12.7M restricted stock units were outstanding, a further source of new shares (10-Q, note 2).

Insider transactions: the Form 4 filings we found for the 12 months to Oct 29, 2026 show no open-market purchases or sales by insiders.

  • The only disposals were about 0.32M shares withheld to pay taxes when restricted stock units vested, worth about $1.45M at the reported prices (our calculation)7.
  • The largest was the interim CEO, Frederick Vogt (about 0.12M shares), followed by the chief commercial and chief operating officers (by shares).
Insider details (Form 4, Dec 1, 2025 to Sep 8, 2026)
  • Shares withheld for taxes, by person: Frederick Vogt, interim CEO, 120,370 (about $0.56M); Daniel Kirby, chief commercial officer, 55,486 (about $0.20M); Igor Bilinsky, chief operating officer, 46,678 (about $0.22M); Friedrich Graf Finckenstein, chief medical officer, 38,539 (about $0.15M); Raj Puri, chief regulatory officer, 36,962 (about $0.19M); Corleen Roche, chief financial officer, 21,238 (about $0.13M).
  • The 31 Form 4 filings listed in note 7 report 319,273 shares withheld for taxes (code F), worth about $1.45M (our calculation); none of them reports an open-market purchase (P) or sale (S) (Form 4 filings).

5. Profit vs cash (latest FY and TTM)

Last updated Nov 12, 2026. Reflects the 10-K FY2025 and the 10-Q Q3 2026 (which includes the first nine months of 2025). Iovance reports no adjusted profit measure.

Iovance’s cash use is close to its net loss: non-cash costs (stock pay and amortisation of the Proleukin rights) are largely offset by cash tied up in customer receivables and capital spending. The net loss shrank by more than 40% in the last 12 months as sales grew, and Q3 cash use was about $9M (our calculation)1.

$M FY2025 Trailing twelve months (TTM) to Sep 30, 2026 (our calculation)8
Net loss −391.0 −220.5
Adjusted metric Not reported Not reported
Operating cash flow −302.4 −190.0
Capital spending −33.8 −26.1
Free cash flow (our calculation)9 −336.2 −216.1

Helps future profit or cash:

  • None identified.

Hurts future profit or cash:

  • Receivables growth used $13.1M of cash in 2025 and $19.7M in H1 2026: sales were recognised before collection; contractual payment terms range from 45 to 105 days.
  • Stock-based pay ($61.6M in 2025, $46.7M TTM): not a cash cost, but a real cost that adds shares (section 4).
  • Recurring amortisation: the 2025 cash-flow statement adds back $23.1M of amortisation, and note 5 reports $22.6M of intangible amortisation excluding acquired-inventory amortisation. At Sep 30, 2026, Iovance estimated $5.6M for the rest of 2026 and $22.5M a year in 2027–30; these charges lower reported profit without a current cash outflow (10-K, note 5; 10-Q Q3 2026, note 4).
  • Iovance must buy a minimum number of Proleukin vials each year through 2028 ($48.2M of purchase obligations at Sep 30); the 2025 cash flow statement added back $13.4M of excess and obsolescence reserves, and note 6 reports $14.3M of inventory reserves, mainly for excess Proleukin under that contract, a cost the contract can repeat.

One-off / no lasting effect:

  • Changes in accrued expenses and other liabilities used $29.7M of cash in H1 2026, reflecting payment timing.
  • 2025 restructuring charges of $5.1M and a $1.0M loan forgiven in 2026.
The raw reconciling items

From the cash flow statements (10-K, Q2 2026 10-Q and Q3 2026 10-Q):

  • Stock-based compensation added back: $61.6M (2025), $34.8M (first nine months of 2026).
  • Amortisation of intangible assets: $23.1M (2025); depreciation $12.9M; right-of-use asset amortisation $11.4M.
  • Excess and obsolescence reserve: $13.4M (2025), $2.8M (H1 2026), mainly Proleukin inventory under the inherited supply contract (10-K, note 6).
  • Working capital, 2025: receivables −$13.1M, inventory −$14.2M, accrued expenses +$28.6M. H1 2026: receivables −$19.7M, inventory −$5.1M, accrued expenses −$29.7M.
  • Gain on loan forgiveness: $1.0M (H1 2026); restructuring charges: $5.1M (2025).

Funding: how long without new money? Cash-burning: Sep 30 cash, cash equivalents and short-term investments of $376.3M covered about 7 quarters of the past year’s free cash outflow of $216.1M (our calculation)10, though Q3 alone used only about $9.2M. Iovance has no debt and no credit line; its own estimate is that cash lasts “well into 2029” (Q3 2026 release).

Funding details
  • As of Sep 30, 2026, the latest filed balance sheet. The company’s “cash position” of about $382M also includes $6.0M of restricted cash held as letter-of-credit collateral for leases, which we leave out (10-Q Q3 2026).
  • Iovance’s estimate is longer than our past-rate path because it expects revenue to keep growing and costs to keep falling: it raised 2026 revenue guidance to $410–420M and expects “significant additional improvements in operating expenses, cost of sales and gross margin in 2026 and 2027” (8-K, Sep 29; Q4 2025 release).
  • The runway estimate has been extended five times since August 2025: Q4 2026 → Q2 2027 → Q3 2027 → “well into 2028” → “into 2H28” → “well into 2029” (Q2 2025, Q3 2025, Q4 2025, Q1 2026, Q2 2026 and Q3 2026 releases).
  • This is based on past cash flow; spending plans can change it.

Extends the runway:

  • None committed. Iovance’s $1.0M note was forgiven in 2026; it has no debt or credit line. The $87.9M raised from share sales in Q3 is already in the Sep 30 cash.

Shortens the runway:

  • None dated: no debt maturities, covenants or acquisition payments due.

Conditional:

  • At-the-market programme: the $350.0M agreement with Jefferies was fully used by Sep 30, 2026 and has terminated; no replacement programme is disclosed (10-Q Q3 2026). Iovance has an automatic shelf registration filed Jun 18, 2026.
  • Payments to Clinigen at double-digit rates on global net sales (as defined in the agreement), for 12 years from 2023, recognised only when probable and estimable; amounts and timing not disclosed (10-K, note 4).

Cash path (our calculation; an illustration, not a forecast):

At the past rate and with known items, cash would fall below zero in Q2 2028; the company itself says its cash will last “well into 2029” (Q3 2026 release), because it expects revenue to keep growing and costs to keep falling, and Q3 alone used only about $9.2M.

Illustration, not a forecast.

Cash path: ending cash by quarter (illustration)Start $376M, Q4 2026 $322M, Q1 2027 $268M, Q2 2027 $214M, Q3 2027 $160M, Q4 2027 $106M, Q1 2028 $52M, Q2 2028 −$2M.Q2 2027: raising window (under a year of usual spending left)Q3 2027: raising window (under a year of usual spending left)Q4 2027: raising window (under a year of usual spending left)Q1 2028: raising window (under a year of usual spending left)Q2 2028: would need new money−$100M$0M$100M$200M$300M$400MStart: $376MQ4 2026: $322MQ1 2027: $268MQ2 2027: $214MQ3 2027: $160MQ4 2027: $106MQ1 2028: $52MQ2 2028: −$2MStartQ4 2026Q1 2027Q2 2027Q3 2027Q4 2027Q1 2028Q2 2028

Ending cash (cash, equivalents and marketable securities) Known item Raising window (under a year of usual spending left) Would need new money

Quarter Starting cash Usual spending Known items Ending cash Sources / notes
Q4 2026 +376.3 −54.0 0.0 +322.3 The Q3 share sales are in the starting cash; no later sale disclosed
Q1 2027 +322.3 −54.0 0.0 +268.3
Q2 2027 +268.3 −54.0 0.0 +214.3
Q3 2027 +214.3 −54.0 0.0 +160.3 Less than a year of usual spending left.
Q4 2027 +160.3 −54.0 0.0 +106.3 Less than a year of usual spending left.
Q1 2028 +106.3 −54.0 0.0 +52.2 Less than a year of usual spending left.
Q2 2028 +52.2 −54.0 0.0 −1.8 Less than a year of usual spending left.

Amounts in $M.

At the past rate and with known items, cash would fall below zero in Q2 2028; the company itself says its cash will last “well into 2029” (Q3 2026 release), because it expects revenue to keep growing and costs to keep falling, and Q3 alone used only about $9.2M. Our path assumes flat spending at the past year’s rate. Companies usually raise money well before that; quarters with less than a year of usual spending left are shaded.

What the cash path counts:

  • Usual spending: about −$54.0M a quarter, held flat; the latest quarter (Q3 2026) used about −$9.2M.
  • Known items: none. Iovance has no debt or dated acquisition payments, and no committed financing to show in a financing table.
How we calculated this

Usual spending is TTM free cash flow (−$216.1M, Q4 2025–Q3 2026) ÷ 4 ≈ −$54.0M a quarter, held flat; no one-off item in the period exceeds 20% of that total, so nothing is removed. Starting cash is cash, cash equivalents and short-term investments at Sep 30, 2026 ($376.3M); the $6.0M of restricted cash is left out because its use is restricted; including it would move the illustrated run-out to Q3 2028. Not added, because past free cash flow already contains them: operating-lease payments and the $48.2M of Proleukin purchase obligations through 2028 (10-Q Q3 2026, contractual obligations). Capital spending is inside usual spending: $26.1M TTM against $33.8M in 2025 and $11.1M in 2024; Iovance has not quantified a capital spending plan. Not included: contingent licence and sales-based payments, including the Clinigen payments, because no payment dates are disclosed. Inherited Proleukin agreements include sales milestones capped at $30M in the US and $15M elsewhere, 25% of which offsets the Clinigen deferred payments; none had been achieved (10-Q Q3 2026, note 11).

6. Customer and contract exposure

Last updated Nov 12, 2026. Reflects the 10-K FY2025 and the 10-Q Q3 2026.

No customer reached 10% of gross revenue in 2025 or the first half of 2026, down from one unnamed customer at 17% in 2024. The main exposures are contracts: sales-based payments to Proleukin’s seller, royalties to the US National Institutes of Health on Amtagvi, and a minimum-purchase supply deal for Proleukin through 2028.

Revenue by product, $M (company figures, approximate)
AmtagviProleukinQ4 2025Q4 2025, Amtagvi: $65MQ4 2025, Proleukin: $22M$87MQ1 2026Q1 2026, Amtagvi: $60MQ1 2026, Proleukin: $11M$71MQ2 2026Q2 2026, Amtagvi: $91MQ2 2026, Proleukin: $9M$100MQ3 2026Q3 2026, Amtagvi: $102MQ3 2026, Proleukin: $20M$122M
Show the data
Label Amtagvi Proleukin Unit
Q4 2025 65 22 $M
Q1 2026 60 11 $M
Q2 2026 91 9 $M
Q3 2026 102 20 $M

Chart source11.

Customer and contract details
  • Customers: Iovance sells mainly to hospitals and clinics, plus distributors and wholesalers in the US. “Customer A” (not named) was 17% of gross revenue in 2024 and 11% in Q2 2025; below 10% in 2025 and H1 2026 (10-K, note 7; 10-Q). About 100 authorised treatment centres offered Amtagvi at Oct 5, 2026 (Oct 2026 presentation).
  • Clinigen (Proleukin seller): deferred payments at double-digit rates on global net sales (as defined in the agreement) over 12 years, then possible earn-outs; the $52.6M approval milestone was paid in Q1 2024 (10-K, note 4).
  • NIH patent licence: royalties on Amtagvi sales from under 1% to mid-single digits, plus milestones; it runs to the last licensed patent’s expiry (10-K, note 15).
  • National Cancer Institute (NCI) cooperative research and development agreement (CRADA): runs to August 2029; either side can end it on 60 days’ notice (10-K, note 15).
  • Boehringer Ingelheim makes Proleukin; since September 2025 Iovance must buy a minimum number of vials each year through Dec 31, 2028 (10-K, Item 1).
  • Other licences: Cellectis (gene editing, for IOV-4001) and Novartis (IOV-3001, a modified IL-2), each with milestones and royalties (10-K, note 15).

7. What to watch

Last updated Nov 12, 2026. Reflects the Q3 2026 release and 10-Q (Nov 5) and the Oct 29 lung cancer update.

Next earnings date: Iovance had not announced its Q4/FY2026 results date as of Nov 12, 2026.

Date Item Source
Nov 2026 POSITILITY, the biomarker-selected lung cancer cohort (target 80 patients), begins enrolling Q3 2026 release
End of 2026 At least 110 authorised treatment centres active; 2026 revenue guide of $410–420M Q3 2026 release
1Q 2027 Possible UK approval (expedited review of the resubmitted application) and possible Swiss approval Q3 2026 release
1H 2027 First results of an investigator-sponsored trial in two skin cancers (cutaneous squamous cell and Merkel cell carcinoma) Q3 2026 release
2027 Planned lung cancer filing (a supplemental biologics license application, or sBLA, to add the use to Amtagvi’s approval), based on about 80 patients; first-line OPTILISM trial start; EU resubmission and a Brazil filing Q3 2026 release
“Well into 2029” End of Iovance’s own cash-runway estimate Q3 2026 release

Valuation at each update

At the close used for each update, from the filings available then. Frozen when the update is published; never revised.

UpdateCloseMarket valueEVP/SEV/salesP/EP/FCFRevenue growthFCF marginNet cash (debt)Basis
Oct 29, 2026$9.56 (Oct 29)$4.3B$4.1B13.4×12.5×n/mn/m+35%−91%$298M12 months to Jun 30, 2026
Nov 12, 2026$7.63 (Nov 12)$3.5B$3.2B9.3×8.3×n/mn/m+51%−57%$376M12 months to Sep 30, 2026

Our calculation from each update's filings (latest at the newest update: 10-Q for the quarter to Sep 30, 2026, filed Nov 5, 2026); not investment advice. n/m = not meaningful (e.g. negative earnings). Hover a heading for its definition. Oct 29, 2026 price: official close, Nasdaq. Nov 12, 2026 price: official close, CNBC, Yahoo Finance.

Notes and calculations

  1. Operating cash flow plus capital spending. Q2 2026 (H1 less Q1): (−$132.9M + $72.1M) + (−$12.0M + $6.6M) = −$66.3M. Q3 2026 (nine months less H1): (−$137.4M + $132.9M) + (−$16.8M + $12.0M) = −$9.2M (10-Q Q3 2026). ↩ ↩2

  2. Shares are common plus convertible preferred as converted: 159.944M at Dec 31, 2021 (157.005M common + 2.842M Series B + 0.097M from Series A) and 464.573M at Sep 30, 2026 (462.543M + 1.933M + 0.097M). Growth = (464.573 ÷ 159.944 − 1) × 100 ≈ 190%; annual rate = [(464.573 ÷ 159.944)^(1 ÷ 4.75) − 1] × 100 ≈ 25.2%; remaining ownership = 1% × 159.944 ÷ 464.573 ≈ 0.34%. ↩

  3. 292.5M shares sold for cash ÷ 304.6M net new shares. ↩

  4. 462.543M ÷ 157.005M − 1. ↩

  5. At-the-market gross = shares × the company’s weighted average price; average received = total gross ÷ total shares. 2022: 29.789M × $6.52 = $194.2M. 2023: $172.5M + 44.080M × $6.99 ($308.1M) = $480.6M ÷ 67.080M = $7.16. 2024: 23.014M × $9.15 ($210.6M) + 23.128M × $8.82 ($204.0M) = $414.6M ÷ 46.142M = $8.98. 2025: 101.899M × $3.07 = $312.8M. 2026: 24.919M × $4.03 ($100.4M) + 14.001M × $3.61 ($50.5M) + 8.667M × $10.34 ($89.6M) = $240.6M ÷ 47.587M = $5.06. ↩

  6. Stock-based compensation ÷ revenue × 100: $109.6M ÷ $164.1M (2024); $61.6M ÷ $263.5M (2025); $34.8M ÷ $292.2M (first nine months of 2026). ↩

  7. Sum of transaction-code F (tax withholding) disposals, transaction dates Dec 1, 2025 to Sep 8, 2026: 319,273 shares × each filing’s reported price ≈ $1.45M. No code S (sale) or P (purchase) transactions were reported. Filings with code F (SEC accession numbers): 0001104659-25-118167, -118168, -118169, -118170; 0001104659-26-014400, -020613, -023535, -023537, -023538, -023539, -024759, -024760, -024762, -024765, -060356, -070149, -070152, -070153, -070155, -071891, -071895, -071897, -071899, -093482, -095040, -105099, -105100, -105101, -106748, -106750, -106752. ↩

  8. FY2025 − 9M 2025 + 9M 2026 (10-K FY2025, 10-Q Q3 2026). Net loss: −$391.0M + $319.1M − $148.6M; operating cash flow: −$302.4M + $249.8M − $137.4M; capital spending: −$33.8M + $24.5M − $16.8M. ↩

  9. Operating cash flow + capital spending, on unrounded filing figures: −$189.950M − $26.105M = −$216.055M (TTM); −$302.408M − $33.836M = −$336.244M (FY2025). ↩

  10. $376.320M ($57.934M cash and cash equivalents + $318.386M short-term investments) ÷ $216.055M ≈ 1.7 years, or about 7 quarters. ↩

  11. Accessed Nov 12, 2026: Q4 2025 release (Q4: US Amtagvi about $65M, global Proleukin about $22M) · Q1 2026 release · Q2 2026 release · Q3 2026 release (Q3: US Amtagvi about $102M, global Proleukin about $20M). The company gives these as approximate (“~”) figures. ↩

Quoting this? You may quote short excerpts under our reuse policy. Please credit WhyMyStockMoved.com and link to this page.

About Iovance Biotherapeutics: Website (external site)Investor relations (external site)SEC filings (external site)Wikipedia (external site)